T. Rowe Price Investment Management Inc. Trims Stake in Teleflex Incorporated $TFX

T. Rowe Price Investment Management Inc. reduced its holdings in Teleflex Incorporated (NYSE:TFX) by 4.6% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,356,754 shares of the medical technology company’s stock after selling 212,289 shares during the quarter. T. Rowe Price Investment Management Inc. owned 9.86% of Teleflex worth $531,699,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Janus Henderson Group PLC increased its position in shares of Teleflex by 2.0% in the fourth quarter. Janus Henderson Group PLC now owns 4,246,112 shares of the medical technology company’s stock worth $518,196,000 after purchasing an additional 84,754 shares during the last quarter. AQR Capital Management LLC lifted its position in Teleflex by 478.1% during the third quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock valued at $287,603,000 after purchasing an additional 1,956,811 shares during the last quarter. State Street Corp lifted its position in Teleflex by 1.5% during the fourth quarter. State Street Corp now owns 1,478,776 shares of the medical technology company’s stock valued at $180,470,000 after purchasing an additional 22,111 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Teleflex by 0.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,250,665 shares of the medical technology company’s stock worth $152,630,000 after buying an additional 5,051 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Teleflex by 10.6% in the 4th quarter. Geode Capital Management LLC now owns 985,684 shares of the medical technology company’s stock worth $120,312,000 after buying an additional 94,679 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Stock Performance

Teleflex stock opened at $126.97 on Friday. The company has a quick ratio of 2.03, a current ratio of 2.55 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $5.62 billion, a PE ratio of -5.57, a P/E/G ratio of 0.93 and a beta of 0.82. The firm has a fifty day simple moving average of $129.54 and a two-hundred day simple moving average of $119.33. Teleflex Incorporated has a twelve month low of $100.18 and a twelve month high of $139.67.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.21 by $0.18. The firm had revenue of $548.30 million for the quarter, compared to analysts’ expectations of $536.91 million. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The company’s revenue for the quarter was up 32.3% compared to the same quarter last year. During the same period last year, the firm earned $1.44 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Research analysts expect that Teleflex Incorporated will post 6.7 EPS for the current year.

Teleflex Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Monday, May 25th will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.1%. The ex-dividend date is Friday, May 22nd. Teleflex’s dividend payout ratio (DPR) is presently -5.96%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on TFX shares. Needham & Company LLC raised their price objective on shares of Teleflex from $138.00 to $147.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Wall Street Zen cut Teleflex from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Piper Sandler upgraded Teleflex from a “neutral” rating to an “overweight” rating and raised their price target for the company from $140.00 to $160.00 in a research report on Monday, June 8th. Wells Fargo & Company lifted their price target on Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Finally, Zacks Research upgraded Teleflex from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $146.00.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.